Direct award for the acquisition of PEGYLATED LIPOSOMAL IRINOTECAN [43 MG/ 10 ML; INJ SOL; VIAL], PEGASPARGASE [3,750 IU; F/AMP], TRIFLURIDINE + TIPIRACILO [15 + 6.14 MG; CAP/ TAB] and TRIFLURIDINE + TIPIRACILO [20 + 8.19 MG; CAP/ TAB]

This tender describes a direct award procedure for the acquisition of several critical oncology medications. The pharmaceuticals include Pegylated Liposomal Irinotecan (43 mg/10 ml, injectable solution in vials), Pegaspargase (3,750 IU, in vials/ampoules), and two formulations of Trifluridine + Tipiracil (15 + 6.14 mg and 20 + 8.19 mg, in capsules/tablets). This is a procurement of pharmaceutical goods. The use of a 'direct award' suggests a specific procurement regulation is being applied, possibly due to urgency, sole-source availability, or prior framework agreements. These medications are vital for cancer treatment regimens. Potential suppliers or distributors of these specific pharmaceutical products are involved in this direct award process. The tender documentation would detail the specific terms and conditions of this direct award.

This is a supplies contract in the health and medical services, transport and logistics and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 19,519.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.